Recent advances in antiretroviral drugs (Q37779092)

23 August 2017

1 reference

title

Recent advances in antiretroviral drugs (English)

1 reference

23 August 2017

anti-retroviral agent

0 references

author name string

Raktim Kumar Ghosh

series ordinal

1

1 reference

23 August 2017

Samhati Mondal Ghosh

series ordinal

2

1 reference

23 August 2017

Shalini Chawla

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

10 August 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

12

1 reference

23 August 2017

1

1 reference

23 August 2017

31-46

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Caring for HIV-infected patients in the ICU in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Novel targets for anti-retroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

HIV-1 integrase and virus and cell DNAs: complex formation and perturbation by inhibitors of integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Lopinavir co-induces insulin resistance and ER stress in human adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

The Place of protease inhibitors in antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Darunavir in treatment-naïve patients. The ARTEMIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Elvitegravir: a new HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Enfuvirtide, a new drug for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Co-receptor switch during HAART is independent of virological success.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Can the further clinical development of bevirimat be justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.509345

10.1517/14656566.2010.509345

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference